JP2023542528A5 - - Google Patents

Info

Publication number
JP2023542528A5
JP2023542528A5 JP2023518781A JP2023518781A JP2023542528A5 JP 2023542528 A5 JP2023542528 A5 JP 2023542528A5 JP 2023518781 A JP2023518781 A JP 2023518781A JP 2023518781 A JP2023518781 A JP 2023518781A JP 2023542528 A5 JP2023542528 A5 JP 2023542528A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
binding protein
polynucleotide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542528A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/051832 external-priority patent/WO2022066965A2/en
Publication of JP2023542528A publication Critical patent/JP2023542528A/ja
Publication of JP2023542528A5 publication Critical patent/JP2023542528A5/ja
Pending legal-status Critical Current

Links

JP2023518781A 2020-09-24 2021-09-23 Sox2抗原を標的とする免疫療法 Pending JP2023542528A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063083069P 2020-09-24 2020-09-24
US63/083,069 2020-09-24
PCT/US2021/051832 WO2022066965A2 (en) 2020-09-24 2021-09-23 Immunotherapy targeting sox2 antigens

Publications (2)

Publication Number Publication Date
JP2023542528A JP2023542528A (ja) 2023-10-10
JP2023542528A5 true JP2023542528A5 (https=) 2024-10-02

Family

ID=78414071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518781A Pending JP2023542528A (ja) 2020-09-24 2021-09-23 Sox2抗原を標的とする免疫療法

Country Status (5)

Country Link
US (1) US20250018036A1 (https=)
EP (1) EP4217387A2 (https=)
JP (1) JP2023542528A (https=)
CN (1) CN116724053A (https=)
WO (1) WO2022066965A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2024148212A2 (en) * 2023-01-06 2024-07-11 The Trustees Of The University Of Pennsylvania T cell receptors directed to sox2 protein
TW202532434A (zh) * 2023-11-15 2025-08-16 南韓商格納西尼有限公司 特異性結合至sox2的單域抗體、包含其之融合蛋白及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
EP3202899B1 (en) 2003-01-28 2020-10-21 Cellectis Custom-made meganuclease and use thereof
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
ES2582091T3 (es) 2005-10-18 2016-09-09 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
WO2010107116A1 (ja) * 2009-03-19 2010-09-23 独立行政法人科学技術振興機構 Sox2由来のhla-a24結合性癌抗原ペプチド
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
US9846162B2 (en) * 2012-05-14 2017-12-19 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
WO2016040724A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN109996868A (zh) 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems

Similar Documents

Publication Publication Date Title
JP2023542528A5 (https=)
CN112300269B (zh) Kras突变特异性t细胞受体筛选及抗肿瘤用途
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2023145589A (ja) 共刺激のための新規のプラットフォーム、新規のcar設計、および養子細胞療法のための他の増強
CA2974998C (en) Chimeric antigen receptors
JP2021168667A (ja) 操作された造血幹細胞/前駆細胞及び非tエフェクター細胞、ならびにその使用
WO2020044239A1 (en) A method to specifically stimulate survival and expansion of genetically-modified immune cells
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
CN110087672A (zh) 免疫调节多肽及相关组合物和方法
JP2022527267A5 (https=)
KR20240032732A (ko) 암 면역요법을 위한 투약 요법
JP2022525925A5 (https=)
JP2022524994A5 (https=)
JP2022523971A5 (https=)
JP2022523553A5 (https=)
JP2022524992A5 (https=)
CN114555815B (zh) T细胞受体及其使用方法
CA3118211A1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CN114502577A (zh) 结合病毒抗原的nk接合器化合物和使用方法
JP2022543059A5 (https=)
CN114450414B (zh) T细胞受体及其使用方法
JP7314161B2 (ja) ゼータカインにより指向性を付与したIL-13受容体α2標的T細胞免疫療法
CN114364806A (zh) T细胞受体及其使用方法
JP2022543060A5 (https=)
JP2023526416A5 (https=)